Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Joe Krupa who wrote (13723)	10/11/2004 2:07:06 PM
From: axial	Read Replies (1) \| Respond to of 14101

Joe, there seems to be quite a gap between negative and not-so-negative (I won't call them positive) views on Dimethaid. We're all just speculating, but I'm inclined to agree with the not-so-negative view. There are a few reasons for this, FWIW: 1 - The reason we advocated change was not just to get rid of the bad - it was also to bring in good management. Many posters seem to take the view that we have merely changed players in a losing game. Those who advocated change (as opposed to simply abandoning their investment) did so for many reasons, but the main one was repeated often: they believed in the drugs. They believed that Dimethaid should have succeeded - and that it still CAN succeed. It seems fairly obvious that new management shares that view - a view that most emphatically includes WF10. 2 - If it's been said once, it's been said a thousand times: the primary reason for Dimethaid's failure was cash starvation. The use of Dr. Guntermann's expertise and advisors should give Dimethaid access to a wide range of superb resources (note: it seems likely that Dimethaid's advisor who commented on the Pennsaid NDA was drawn from these resources). Message 20507658 bioalliance.de Over time, The Street will assess Dimethaid's new management, which appears to be a combination of pragmatic business with biotech expertise, turnaround expertise - and internal financing sources. Should they start making the right decisions (and the beginning looks promising) The Street will respond: they'll want to work with Dimethaid, and they'll step forward with money. IMO you're absolutely right. In time, the analysts will reappear, and so will the institutional investment. Effective and energetic management, combined with sound financing and the confidence of The Street equals success. It's true we're not there yet; the road still looks rocky, but it can be done. 3 -* Partnerships. Standstill Agreement with JnJ terminated unilaterally by Dimethaid. What does MacNeil do? They want to talk. How many times has it been posted what a great partnership it could be if JnJ wanted to get in on both Pennsaid and Penecure? Solvay terminated the agreement, and was ready to litigate against Dimethaid (thanks RK: Provalis revisited). Now they want to talk. Nobody is suggesting there's a done deal, here. But to go from terminated agreements and potential litigation, to preliminary discussions on new agreements with two major potential partners is quite a turnaround. Especially in a short few weeks. Dan Chicoine himself was careful not to overstate the potential at Dimethaid. Nobody is going overboard with their projections. We're all still walking through a minefield - but it looks like we can see a few paths to the other side. There's little reason for us to be hostages to the paranoid psychology that used to surround Dimethaid. Changing management was the right thing to do. Having done the right thing, and having recently been informed of the dangers and difficulties we face, we now have a pretty sober assessment of present difficulties and future possibilities. There's reason - good reason for optimism. Not dancing in the streets, not wild enthusiasm - just clear-eyed careful optimism. Good post Joe. Jim